AEMD/CPI-613
Cornerstone’s proprietary Altered Energy Metabolism Directed (AEMD) drug platform disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential “bioenergetic” differences are linked to pathways that control, among other things, cancer cell growth and development, as well as various forms of cell death, including apoptosis (programmed cell death) and necrosis. The platform is designed to produce drugs, such as the company’s lead drug CPI-613, that catastrophically disrupt energy-production pathways specific to cancer cells.
CPI-613
CPI-613 is the lead candidate from a new chemical class that, through a novel mechanism of action, targets metabolic changes considered to be common to many, if not all, cancer types. CPI-613 is currently being evaluated in several ongoing Phase I/II trials.
CPI-613 was granted orphan drug status by the US FDA for pancreatic cancer, which has a poor prognosis, spreads rapidly and often goes undetected in its early stages. In November of 2009, the drug was named one of the “top most interesting oncology projects available for partnering” by Windhover Information, a leading provider of healthcare industry analysis.
Key features of CPI-613 shown in preclinical testing:
- Active across a broad spectrum of cancer types (solid tumor and hematologic)
- Induces cancer cell death in animal models of human cancers with no toxic effect on normal cells at therapeutic levels
- Demonstrates 100% efficacy against every human cancer type tested in cell culture
For more information: CPI-613/AEMD fact sheet
